Literature DB >> 12556648

Opportunity for JNC VII.

Joel Handler1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2003        PMID： 12556648      PMCID： PMC8099277          DOI： 10.1111/j.1524-6175.2003.02190.x

Source DB:  PubMed          Journal:  J Clin Hypertens (Greenwich)        ISSN： 1524-6175            Impact factor:   3.738


× No keyword cloud information.
  9 in total

1.  Reporting of 6-month vs 12-month data in a clinical trial of celecoxib.

Authors:  J B Hrachovec; M Mora
Journal:  JAMA       Date:  2001-11-21       Impact factor: 56.272

2.  Sponsorship, authorship, and accountability.

Authors:  F Davidoff; C D DeAngelis; J M Drazen; M G Nicholls; J Hoey; L Højgaard; R Horton; S Kotzin; M Nylenna; A J Overbeke; H C Sox; M B Van Der Weyden; M S Wilkes
Journal:  N Engl J Med       Date:  2001-09-13       Impact factor: 91.245

3.  Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes.

Authors:  E J Lewis; L G Hunsicker; W R Clarke; T Berl; M A Pohl; J B Lewis; E Ritz; R C Atkins; R Rohde; I Raz
Journal:  N Engl J Med       Date:  2001-09-20       Impact factor: 91.245

4.  A national survey of provisions in clinical-trial agreements between medical schools and industry sponsors.

Authors:  Kevin A Schulman; Damon M Seils; Justin W Timbie; Jeremy Sugarman; Lauren A Dame; Kevin P Weinfurt; Daniel B Mark; Robert M Califf
Journal:  N Engl J Med       Date:  2002-10-24       Impact factor: 91.245

5.  The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes.

Authors:  H H Parving; H Lehnert; J Bröchner-Mortensen; R Gomis; S Andersen; P Arner
Journal:  N Engl J Med       Date:  2001-09-20       Impact factor: 91.245

6.  Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy.

Authors:  B M Brenner; M E Cooper; D de Zeeuw; W F Keane; W E Mitch; H H Parving; G Remuzzi; S M Snapinn; Z Zhang; S Shahinfar
Journal:  N Engl J Med       Date:  2001-09-20       Impact factor: 91.245

7.  Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol.

Authors:  Lars H Lindholm; Hans Ibsen; Björn Dahlöf; Richard B Devereux; Gareth Beevers; Ulf de Faire; Frej Fyhrquist; Stevo Julius; Sverre E Kjeldsen; Krister Kristiansson; Ole Lederballe-Pedersen; Markku S Nieminen; Per Omvik; Suzanne Oparil; Hans Wedel; Peter Aurup; Jonathan Edelman; Steven Snapinn
Journal:  Lancet       Date:  2002-03-23       Impact factor: 79.321

8.  Comments on medical research and the publication of scientific papers.

Authors:  M Moser
Journal:  J Clin Hypertens (Greenwich)       Date:  2001 Sep-Oct       Impact factor: 3.738

Review 9.  Premature termination of clinical trials--lessons learned.

Authors:  D A Sica
Journal:  J Clin Hypertens (Greenwich)       Date:  2002 May-Jun       Impact factor: 3.738
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.